We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Delaware Bill Seeks Fee On Opioid Makers Amid Health Crisis

Law360 (March 14, 2019, 7:41 PM EDT) -- New legislation filed in the Delaware Senate would impose a per-pill opioid impact fee on drug manufacturers and use the proceeds to defray the state’s costs, including addiction and prevention services.

In filing S.B. 34 on Tuesday, Sen. Stephanie Hansen, D-Middletown, is proposing a two-tiered impact fee that would vary with the strength of the medication and whether it was sold as a brand-name or generic prescription.

The new levy would be assessed at a rate of one penny per morphine milligram equivalent, or MME, for name brand opioids and one-quarter of a penny per MME for generics, according to the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS